Latest news with #DilipShanghvi
Time of India
07-07-2025
- Business
- Time of India
Sun Pharma says working towards full regulatory resolution at 3 plants facing USFDA action
Drug major Sun Pharmaceutical Industries aims to bolster compliance across its manufacturing operations and work towards achieving full regulatory resolution at the three facilities facing USFDA action, according to Chairman and MD Dilip Shanghvi. In his address to shareholders in its annual report for 2024-25, Shanghvi said the company is facing US Food and Drug Administration (USFDA) compliance-related issues at three of its facilities. The company is facing an import alert for the Halol facility and also is in receipt of non-compliance letter for the Mohali facility , he stated. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Shape your journey in the unforgiving desert world of Arrakis! Shop Now Undo Additionally, the company's Dadra facility was accorded an Official Action Indicated (OAI) status in FY24, he noted. "We have completed the implementation of Corrective and Preventive Action (CAPA) in the Halol facility, which is currently awaiting USFDA inspection, and we are in the process of implementing CAPA at the Mohali and Dadra facilities," he added. Live Events Besides these three, all facilities remain compliant with global regulatory standards, including those of the US FDA, Shanghvi said. On the business front, he noted the company expects its R&D investment to be in the range of 6-8 per cent of sales in the current financial year, with enhanced focus on speciality products. The company aims to expand its product pipeline of global speciality products, he added. "Our R&D spend in FY26 is likely to be in the range of 6-8 per cent of sales, with increased spending expected on speciality products," Shanghvi stated. The Mumbai-based drug major invested USD 154 million on speciality products R&D in FY25. Sun Pharma reported consolidated revenues of Rs 52,041 crore in FY25, with the share of global speciality business increasing from 18 per cent in FY24 to 20 per cent in FY25 sales. The company sells speciality products like Ilumya, Winlevi, Cequa and Odomzo across markets. "We anticipate mid to high single-digit consolidated topline growth in FY26, and expect our global speciality business to continue on its growth path," Shanghvi said. Elaborating on the focus areas, he said the company plans to prepare the business for potential disruptions arising from tariffs and geopolitical issues. The company would also continue to focus on cost and operational efficiency, he added.
Time of India
04-07-2025
- Health
- Time of India
Hassan heart attack death cases: India's top drugmakers rally behind Covid vaccines
Leading drugmakers on Thursday rallied in support of Covid vaccines , using various social media platforms, amid a series of deaths in Karnataka's Hassan district due to heart attacks. Dilip Shanghvi, chairman and managing director at Sun Pharmaceuticals said in a post on LinkedIn, 'The deaths of multiple young individuals in one district of Karnataka due to cardiac ailments are unfortunate. While this appears to be specific to the district, linking it to the Covid-19 vaccine without any scientific evidence is "incorrect and misleading". "India's vaccine approval process is rigorous and science-driven, and we must continue to have confidence in it. The vaccine has been administered to millions across the country. If there were a connection, we would have seen similar incidents in many other places — which is not the case. The State health authorities should thoroughly investigate the situation to determine the cause,' Sanghavi said. Sorting to allay the apprehensions, Pankaj Patel, chairman, Zydus Lifesciences , which also manufactures Covid DNA vaccine, said in a post on X, 'There are other multiple reasons like age, environmental factors, genetics, lifestyle etc, that could be the leading cause of heart attacks in people. Several scientific studies globally and in India have conclusively shown that the risk of heart attack or myocarditis is greater after SARS-CoV-2 infection. #Vaccines save lives.' Appreciating the vaccination programme, Patel said, "the massive vaccination programme in our country during the peak of Covid phase saved millions of people and families. In fact a study published in Lancet estimated that India averted almost 3.4 million deaths due to vaccination in the year 2021," he said. Live Events Satish Reddy, chairman, Dr Reddy's Laboratories, wrote, 'India-made vaccines are by WHO and used worldwide. They helped end polio and fight Covid. At a time when India is seen as a vaccine leader, let's build trust in science, not doubt it. Public health must stay above politics.' A post on X attributed to Samir Mehta, executive chairman, Torrent Pharma said, 'India has earned global recognition as the Pharmacy of the World, supplying safe and effective vaccines to over 90 countries…Let's not allow misinformation to erode trust in science or the integrity of India's healthcare ecosystem.' Responding to rising concerns over the sudden deaths of more than 20 people in Hassan district, the Karnataka health department formed an expert committee to probe a possible link to Covid vaccines. However, support came pouring in for Covid vaccines. The Indian Vaccine Manufacturers Association said Covid-19 vaccines were developed and manufactured in the country with the highest safety and quality standards. Assuring about the safety of these vaccines, Dr/ G.V.J.A. Harshavardhan, director general at the association said the approvals were based on extensive evaluation in preclinical studies and human clinical trials with positive results on safety, efficacy, and immunogenicity of the vaccines. 'Patient safety and product quality are always prioritised during the vaccine development and its manufacture,' he said in a statement. He said prior to releasing the vaccines, they were tested extensively for safety by the manufacturers and are also provided batch release certification by the Central Drugs Laboratory (CDL) of the Ministry of Health and Family Welfare. Sudarshan Jain, secretary general, Indian Pharmaceutical Alliance (IPA) said during the pandemic, vaccines played a crucial role, and India consistently supplied medicines and vaccines across the world. "These vaccines have been well documented and rigorously tested as per regulatory processes. Misinformation and distortion of facts endanger public health and undermine the trust built on science and patient care globally".
Time of India
03-07-2025
- Health
- Time of India
Pharma rivals unite to back Made-in-India vaccines
NEW DELHI: Pharma promoters may be competing fiercely in the market, but on Thursday they all rallied behind domestically- manufactured vaccines, including those for polio and Covid-19. Satish Reddy, chairman of Dr Reddy's Laboratories, Dilip Shanghvi, promoter and CMD of Sun Pharma, Pankaj Patel chairman and promoter of Zydus Lifesciences, and Torrent Pharma chairman Samir Mehta —industry leaders known for their media reticence—each took to social media platforms to endorse India-made vaccines. These comments come amid rising concerns over sudden deaths in Karnataka, and claims that Covid-19 vaccines might be associated with heart attacks. In separate posts, they highlighted that these vaccines are safe, effective, and trusted in over 90 countries, backed by the World Health Organization (WHO), and widely used across the globe. India accounts for 60% of global vaccine production. During the Covid pandemic, vaccines played a crucial role, and India supplied vaccines and critical medicines across the world. Linking the deaths to the COVID-19 vaccine without any scientific evidence is incorrect and misleading, they added. ``They helped end polio & fight COVID. At a time when India is seen as a vaccine leader, let's build trust in science, not doubt it. Public health must stay above politics'', Reddy said in a post on micro-blogging site, X. Interestingly, all comments were posted on the same day, which is unprecedented. Patel said on X ``There are other multiple reasons like age, environmental factors, genetics, lifestyle etc, that could be the leading cause of heart attacks in people. Several scientific studies globally and in India have conclusively shown that the risk of heart attack or myocarditis is greater after SARS-CoV-2 infection. It has been proven beyond doubt that vaccination remains the most effective and preventive healthcare strategy to reduce deaths and disabilities''. ``The vaccine has been administered to millions across the country. If there were a connection, we would have seen similar incidents in many other places - which is not the case. The state health authorities should thoroughly investigate the situation to determine the cause'', Shanghvi stated in a Linkedin post. Batting for the ``knowledge-driven sector which plays a vital role in global health'', Indian Pharmaceutical Alliance secretary general Sudarshan Jain said ``Misinformation and distortion of facts endanger public health and undermine the trust built on science and patient care globally''. Further, Biocon chairperson Kiran Mazumdar-Shaw said in a post on X that COVID-19 vaccines developed in India were approved, following ``rigorous protocols''. She debunked Karnataka chief minister Siddaramaiah's view which linked heart-related deaths in Hassan to Covid vaccine. O n July 1, he had said "hasty approval and distribution" of the vaccine to the public could also be a reason for the multiple deaths. UK major AstraZeneca had also licensed Pune-based Serum Institute of India to manufacture the Covid-19 vaccine, which was sold as Covishield in the country. It was also shipped to several countries as part of the govt's `Vaccine Maitri' initiative. Earlier, the health ministry said that extensive studies by the Indian Council of Medical Research and All India Institute of Medical Sciences have conclusively established no linkage between COVID-19 vaccines, and sudden deaths among adults post-COVID-19.
India.com
20-06-2025
- Business
- India.com
Meet woman, daughter of India's richest pharma tycoon, she now leads Rs 3950000000000 company, she is…, her business is…
Vidhi Shanghvi, Sun Pharma Vidhi Shanghvi is daughter of Dilip Shanghvi, a famous Pharma businessman. She is in headlines for her role in Sun Pharma, one of India's biggest pharmaceutical companies. His net worth is around $25 billion and known as India's richest pharma billionaire. He is also among the top 100 richest people in the world. But now, his daughter Vidhi Shanghvi has also started handling his business. Who Is Vidhi Shanghvi? Vidhi Shanghvi is an Executive Director in Sun Pharma. After 13 years of experience, she now leads Sun Pharma's Consumer Healthcare and India Distribution. Sun Pharma was founded by her father, Dilip Shanghvi in 1983. They started making psychiatric drugs and slowly became India's most valuable pharma company, with a market capitalisation of Rs 3.95 lakh crore. Vidhi was recently appointed as Whole-time Director for a five-year term. Vidhi Shanghvi Educational Background Vidhi graduated from the Wharton School at the University of Pennsylvania. In Sun Pharma, she used her education in marketing and consumer healthcare. She began her career at Sun Pharma in 2012 as a Brand Manager in the India Business division. Over the years, she has held several leadership positions. In 2014, she became the Marketing Head for one of the company's Cardiovascular Business Units. She also handled many marketing campaigns. After the merger of Ranbaxy with Sun Pharma, Vidhi Shanghvi became the Business Head of the company's Consumer Healthcare Division. She has played a big role in the growth of the products like Revital H and Volini in retail stores, pharmacies, and online platforms in India. She also has expertise in various fields like marketing, brand building, project and alliance management, and distribution. She is the founder of Mann Talks, a not-for-profit mental health initiative. This platform gives free, holistic mental health solutions to individuals for their mental well-being.
Time of India
18-06-2025
- Business
- Time of India
Meet Vidhi Shanghvi, daughter of India's richest pharma tycoon, steering a Rs 3.95 lakh crore company
Vidhi Shanghvi, daughter of India's pharma tycoon Dilip Shanghvi, is making headlines for her impressive role in Sun Pharma, one of India's biggest pharmaceutical companies. With a net worth of $25 billion, Dilip Shanghvi is India's richest pharma billionaire and among the top 100 richest people in the world. But now, all eyes are on his daughter Vidhi Shanghvi, who is slowly stepping into the limelight with her strong leadership and modern approach to business. Who is Vidhi Shanghvi? Vidhi Shanghvi is currently the Executive Director at Sun Pharma, a company founded by her father, Dilip Shanghvi in 1983. Sun Pharma started as a maker of psychiatric drugs and has grown to become India's most valuable pharma company, with a market capitalisation of ₹3.95 lakh crore. Vidhi was recently appointed as Whole-time Director for a five-year term, showing her growing influence within the company. Educational Background of Vidhi Shanghvi Following the footsteps of many billionaire heirs, Vidhi Shanghvi studied abroad to gain global exposure. She graduated from the prestigious Wharton School at the University of Pennsylvania, a top business school in the world. Her academic background has helped her bring fresh and innovative ideas to Sun Pharma, especially in areas like marketing and consumer healthcare. Career Journey at Sun Pharma Vidhi Shanghvi began her career at Sun Pharma in 2012 as a Brand Manager in the India Business division. Over the years, she has held several leadership positions. In 2014, she became the Marketing Head for one of the company's Cardiovascular Business Units. She led many successful marketing campaigns and was instrumental in improving business operations and initiating digital transformation projects. Leading Sun Pharma's Consumer Healthcare and Distribution In 2015, after the merger of Ranbaxy with Sun Pharma, Vidhi Shanghvi was made the Business Head of the company's Consumer Healthcare Division. Under her leadership, this division has grown rapidly. She has played a key role in boosting the presence of popular products like Revital H and Volini across retail stores, pharmacies, and online platforms in India. Apart from Consumer Healthcare, Vidhi Shanghvi also leads India Distribution – a crucial part of Sun Pharma's value chain. Her efforts have helped improve supply efficiency and expand reach across the country. Over 13 Years of Experience in Pharma Sector With more than 13 years of professional experience, Vidhi Shanghvi has built expertise in various fields, including marketing, brand building, project and alliance management, and distribution. Her dynamic leadership style and strategic thinking have earned her recognition within the industry. Vidhi Shanghvi's Passion for Mental Health Beyond her corporate role at Sun Pharma, Vidhi Shanghvi is also deeply committed to mental health. She is the founder of Mann Talks, a not-for-profit mental health initiative. This platform provides free, holistic mental health solutions and encourages individuals to take charge of their mental well-being. What is Dilip Shanghvi's Net Worth? Dilip Shanghvi, founder of Sun Pharma, has an estimated net worth of $25.8 billion, according to Forbes. As of today, June 18, he is the 77th richest person in the world and remains one of the most successful entrepreneurs in India. His vision and leadership have shaped Sun Pharma into a global pharmaceutical giant. Vidhi Shanghvi's Brother Also Plays a Key Role Vidhi Shanghvi's brother, Aalok Shanghvi, is also part of the leadership at Sun Pharma. A few months ago, he was promoted to the position of Chief Operating Officer (COO), making it a truly family-led business. Vidhi Shanghvi is clearly following in the footsteps of her father Dilip Shanghvi, but she is also building her own legacy at Sun Pharma. With a strong academic background, diverse industry experience, and a clear passion for healthcare and innovation, Vidhi Shanghvi is emerging as a powerful new-age leader in the Indian pharmaceutical sector.
